Un­en­cum­bered by safe­ty con­cerns, Roche's Hem­li­bra gets break­through sta­tus for new pa­tient group

Re­cent safe­ty con­cerns have not stopped Roche from ob­tain­ing a speedy FDA re­view for us­ing Hem­li­bra to treat he­mo­phil­ia A pa­tients with­out fac­tor VI­II in­hibitors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER